The Pennant Group (PNTG) Competitors $24.64 -0.53 (-2.11%) Closing price 04:00 PM EasternExtended Trading$24.66 +0.02 (+0.10%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PNTG vs. SGRY, WGS, CON, PRVA, VCYT, ADUS, PGNY, CELC, ARDT, and LFSTShould you be buying The Pennant Group stock or one of its competitors? The main competitors of The Pennant Group include Surgery Partners (SGRY), GeneDx (WGS), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), Veracyte (VCYT), Addus HomeCare (ADUS), Progyny (PGNY), Celcuity (CELC), Ardent Health (ARDT), and LifeStance Health Group (LFST). These companies are all part of the "healthcare" industry. The Pennant Group vs. Its Competitors Surgery Partners GeneDx Concentra Group Holdings Parent Privia Health Group Veracyte Addus HomeCare Progyny Celcuity Ardent Health LifeStance Health Group Surgery Partners (NASDAQ:SGRY) and The Pennant Group (NASDAQ:PNTG) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Which has preferable valuation and earnings, SGRY or PNTG? The Pennant Group has lower revenue, but higher earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurgery Partners$3.24B0.91-$168.10M-$1.43-16.11The Pennant Group$695.24M1.22$22.56M$0.7831.59 Do insiders & institutionals hold more shares of SGRY or PNTG? 85.9% of The Pennant Group shares are owned by institutional investors. 2.7% of Surgery Partners shares are owned by company insiders. Comparatively, 5.4% of The Pennant Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is SGRY or PNTG more profitable? The Pennant Group has a net margin of 3.36% compared to Surgery Partners' net margin of -5.57%. The Pennant Group's return on equity of 9.85% beat Surgery Partners' return on equity.Company Net Margins Return on Equity Return on Assets Surgery Partners-5.57% 2.51% 1.01% The Pennant Group 3.36%9.85%4.04% Does the media favor SGRY or PNTG? In the previous week, Surgery Partners had 8 more articles in the media than The Pennant Group. MarketBeat recorded 9 mentions for Surgery Partners and 1 mentions for The Pennant Group. Surgery Partners' average media sentiment score of 1.18 beat The Pennant Group's score of 0.94 indicating that Surgery Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surgery Partners 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive The Pennant Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, SGRY or PNTG? Surgery Partners has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, The Pennant Group has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Do analysts rate SGRY or PNTG? Surgery Partners currently has a consensus target price of $33.00, suggesting a potential upside of 43.23%. The Pennant Group has a consensus target price of $33.40, suggesting a potential upside of 35.55%. Given Surgery Partners' stronger consensus rating and higher probable upside, analysts plainly believe Surgery Partners is more favorable than The Pennant Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surgery Partners 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67The Pennant Group 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryThe Pennant Group beats Surgery Partners on 9 of the 16 factors compared between the two stocks. Get The Pennant Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PNTG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PNTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PNTG vs. The Competition Export to ExcelMetricThe Pennant GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$851.56M$5.35B$5.76B$9.72BDividend YieldN/A1.25%4.40%4.10%P/E Ratio31.5926.6230.1925.84Price / Sales1.22173.95473.64122.75Price / Cash27.3027.2125.7828.79Price / Book2.714.589.425.99Net Income$22.56M$189.47M$3.27B$265.29M7 Day Performance-1.87%1.86%2.05%2.53%1 Month Performance5.52%14.47%3.58%0.93%1 Year Performance-29.52%15.13%30.09%18.70% The Pennant Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PNTGThe Pennant Group3.809 of 5 stars$24.64-2.1%$33.40+35.6%-28.0%$851.56M$695.24M31.597,000SGRYSurgery Partners2.9968 of 5 stars$22.74-3.8%$33.00+45.1%-29.8%$3.03B$3.11B-15.9015,000News CoverageWGSGeneDx2.1771 of 5 stars$110.54+5.1%$101.63-8.1%+259.8%$3.02B$305.45M2,210.801,200Positive NewsInsider TradeCONConcentra Group Holdings Parent2.268 of 5 stars$21.47-0.7%$28.50+32.7%+1.0%$2.77B$1.90B18.0411,250Positive NewsPRVAPrivia Health Group4.2234 of 5 stars$20.31-1.3%$28.00+37.9%+5.4%$2.53B$1.74B184.651,140News CoverageVCYTVeracyte2.7792 of 5 stars$27.99+2.3%$40.90+46.1%-3.1%$2.15B$445.76M84.82790News CoveragePositive NewsADUSAddus HomeCare4.9247 of 5 stars$111.95+1.6%$142.86+27.6%-11.4%$2.03B$1.15B24.7149,703News CoverageAnalyst ForecastPGNYProgyny2.3615 of 5 stars$21.75-4.8%$24.90+14.5%+7.9%$1.96B$1.17B36.86310Positive NewsCELCCelcuity1.0044 of 5 stars$46.66+1.7%$39.20-16.0%+202.1%$1.79BN/A-15.4040ARDTArdent Health3.3529 of 5 stars$12.04+1.3%$19.56+62.5%-25.1%$1.70B$5.97B6.6524,900LFSTLifeStance Health Group3.1599 of 5 stars$4.57+4.6%$8.50+86.0%-10.2%$1.70B$1.25B-91.4010,218 Related Companies and Tools Related Companies SGRY Competitors WGS Competitors CON Competitors PRVA Competitors VCYT Competitors ADUS Competitors PGNY Competitors CELC Competitors ARDT Competitors LFST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PNTG) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Pennant Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share The Pennant Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access